Completed PHASE2 INTERVENTIONAL 2-arm NCT00057304

Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus

A Phase II Randomized, Double-Blind, Dose-Ranging Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus

Sponsor: Hoffmann-La Roche

Conditions Diabetes

Interventions RO 205-2349

Updated 8 times since 2017 Last updated: Apr 27, 2023 Started: Jun 30, 2003 Primary completion: Mar 31, 2004 Completion: Mar 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Diabetes, this trial is completed. The trial is conducted by Hoffmann-La Roche and has accumulated 8 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — May 2023 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Mar 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Mar 2017 [monthly]

Completed PHASE2

First recorded

Jun 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arad, Romania , Bracknell, United Kingdom , Brasov, Romania , Bucharest, Romania , Camp Hill, United States , Chihuahua, Chih., Mexico , Craiova, Romania , Dallas, United States , Durham, United States , Galati, Romania and 28 more locations